SEC Form 4 · accession 0000899243-18-011945
Amneal Pharmaceuticals, Inc. · AMRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert L Burr
Director
Period of report
May 4, 2018
Accepted (ET)
May 8, 2018 · 7:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001723128
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF1 | May 4, 2018 | A | 60,475 | — | A | 60,475 | D | |
| Class A Common StockF2 | May 4, 2018 | A | 6,057 | — | A | 6,057 | I | By the Robert L. Burr IRA Account |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF4,F3 | $16.40 | May 4, 2018 | A | 10,575 | A | — | May 16, 2027 | Class A Common Stock | 10,575 | 10,575 | D |
| Stock OptionF4,F3 | $30.33 | May 4, 2018 | A | 10,575 | A | — | May 17, 2026 | Class A Common Stock | 10,575 | 10,575 | D |
| Stock OptionF4,F3 | $44.85 | May 4, 2018 | A | 7,300 | A | — | May 12, 2025 | Class A Common Stock | 7,300 | 7,300 | D |
| Stock OptionF4,F3 | $25.24 | May 4, 2018 | A | 11,500 | A | — | May 14, 2024 | Class A Common Stock | 11,500 | 11,500 | D |
| Stock OptionF4,F3 | $17.99 | May 4, 2018 | A | 12,000 | A | — | May 15, 2023 | Class A Common Stock | 12,000 | 12,000 | D |
| Stock OptionF4,F3 | $20.90 | May 4, 2018 | A | 10,000 | A | — | May 23, 2022 | Class A Common Stock | 10,000 | 10,000 | D |
| Stock OptionF4,F3 | $27.97 | May 4, 2018 | A | 10,000 | A | — | May 11, 2021 | Class A Common Stock | 10,000 | 10,000 | D |
| Stock OptionF4,F3 | $20.30 | May 4, 2018 | A | 10,000 | A | — | May 26, 2020 | Class A Common Stock | 10,000 | 10,000 | D |
| Stock OptionF4,F3 | $6.55 | May 4, 2018 | A | 30,000 | A | — | May 20, 2019 | Class A Common Stock | 30,000 | 30,000 | D |
| Stock OptionF5 | $15.01 | May 7, 2018 | A | 24,977 | A | — | May 7, 2028 | Class A Common Stock | 24,977 | 24,977 | D |
| Restricted Stock UnitsF6,F7 | — | May 7, 2018 | A | 6,107 | A | — | — | Class A Common Stock | 6,107 | 6,107 | D |
Explanation of responses
- F1Received in exchange for 60,475 shares of Impax Laboratories, Inc. ("Impax") common stock pursuant to the Business Combination Agreement, dated as of October 17, 2017, among Impax, Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and K2 Merger Sub Corporation (as amended, the "BCA").
- F2Received in exchange for 6,057 shares of Impax common stock pursuant to the BCA.
- F3The option is vested and currently exercisable.
- F4Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock.
- F5The option vests in four equal annual installments beginning on May 07, 2019.
- F6Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- F7The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date.